On October 5, 2021 Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will present clinical and translational data from the Phase 2 SPEARHEAD-1 trial at the Connective Tissue Oncology Society (CTOS) meeting(Press release, Adaptimmune, OCT 5, 2021, View Source [SID1234590810]). The Company will also present translational data based on the patients for whom safety and efficacy were recently reported at ESMO (Free ESMO Whitepaper) from the Phase 1 SURPASS trial, as well as a data update from the four patients treated in the Radiation sub-study of the Phase 1 trial with afami-cel, at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) meeting. Abstracts are available online on the meetings’ web sites.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"At CTOS, we will present clinical and translational data updates from our SPEARHEAD-1 trial. Data from this trial will form the basis of our first BLA submission next year for afami-cel in synovial sarcoma and MRCLS," said Elliot Norry, Adaptimmune’s Chief Medical Officer. "During SITC (Free SITC Whitepaper), we will present translational data from the SURPASS trial with our next-gen therapy ADP-A2M4CD8, as well as clinical data from a sub-study combining low-dose radiation with afami-cel. These two trials represent investigational approaches to improving the potency of our SPEAR T-cells. Understanding how we can continually enhance our T-cell therapies, so as to ultimately improve clinical outcomes for patients, is a key focus of our translational and early phase clinical research."
CTOS Meeting
Abstract Title: SPEARHEAD-1: A Phase 2 trial of afamitresgene autoleucel (formerly ADP-A2M4) in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma (Abstract #1080870)
Oral presentation: November 12, 2021, in the Immunotherapy & Immune Microenvironment Session starting at 10:00 a.m. EST. Presenter: Dr. Brian Van Tine, Associate Professor of Medicine at Washington University School of Medicine in St. Louis
Abstract Title: SPEARHEAD-1 preliminary translational insights from a Phase 2 trial of afamitresgene autoleucel (formerly ADP-A2M4) in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma (Abstract #1080366)
Poster Presentation: November 12, 2021, 2:30 p.m. – 3:15 p.m. EST during the Immunology & Immunotherapy Session. Presenter: Dr. Sandra D’Angelo, Medical Oncologist at Memorial Sloan Kettering Cancer Center
At CTOS, Adaptimmune will host its first virtual medical symposium on Thursday, November 11, 4:30-6:30 p.m. EST.
SITC meeting
Abstract Title: Enhancement of TCR-engineered T-cells targeting MAGE-A4 antigen by co-expression of CD8α and inhibition of AKT signaling during ex vivo T-cell expansion (Abstract #373)
Poster presentation: November 12-14, 2021, 7:00 a.m – 5:00 p.m. EST. Presenter: Alex Tipping, Adaptimmune
Abstract Title: Radiation sub-study to characterize safety and tolerability of low-dose radiation in combinations with afami-cel in patients with advanced cancers (Abstract #376)
Poster Presentation: November 12-14, 2021, 7:00 a.m. – 5:00 p.m. EST. Presenter: Dr. James W. Welsh, Professor, Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center